Biopharmaceutical Industry Facing Hiring Difficulties and R&D Talent Gap, Finds PwC Health Research Institute ReportFebruary 4, 2013 8:00 am | News | Comments
A talent gap in the scientific workforce has biopharmaceutical companies searching outside for fresh skills and alternate approaches to R&D staffing, according to PwC's Health Research Institute (HRI) in a new report published today. New R&D organizational models based on partnerships, alliances and even crowd sourcing are changing talent needs.
Eli Lilly & Co. said Tuesday that President, CEO and Chairman John Lechleiter will have...
Eli Lilly & Co. said Tuesday that President, CEO and Chairman John Lechleiter will have...
Valeant Pharmaceuticals Announces Resignation of Dr. Laurence Paul from Valeant's Board of DirectorsMay 16, 2013 7:56 am | News | Comments
Valeant Pharmaceuticals International, Inc. announced that Dr. Laurence Paul has resigned from Valeant's Board of Directors due to expanded business, philanthropic, and personal commitments. Dr. Paul was originally elected to Biovail Corporation's Board of Directors in June 2002 where he served in several capacities.
Drug and medical device maker Hospira Inc. said Tuesday that Dr. Sumant Ramachandra was coming back as senior vice president and chief scientific officer, just two months after he had left the company. Ramachandra, 44, had left Hospira in March to be president of research and development at...
WebMD Health Corp. said Tuesday that CEO Cavan Redmond is leaving the company after less than a year on the job. Redmond is stepping down as CEO and from the board of directors effective immediately. David Schlanger, WebMD's head of strategic and corporate development, will take over as interim...
The creator of Orajel, a medicine aimed at fighting toothaches that was later also used for mouth sores, has died, family members said Sunday. David Morris Kern was 103. Born in 1909 in Manhattan and raised in Brooklyn, Kern graduated from the Brooklyn College of Pharmacy and worked as a pharmacist before becoming a salesman for Norwich and Warner Pharmaceuticals.
Teva Pharmaceuticals Industries Ltd. says it will close an eastern Pennsylvania plant that employs nearly 500 people. Teva said last year it wanted to cut costs by around $2 billion over five years. The drugmaker had previously halted plans to build a $300 million distribution center in Northeast Philadelphia, a project that was to bring 400 jobs to the area.
Herbalife, maker of nutritional and weight loss supplements, said Thursday that two representatives of billionaire investor Carl Icahn will join its board of directors. The company said Jonathan Christodoro and Keith Cozza were elected to serve two-year terms on the board at Herbalife's annual...
Novartis plans to trim production and cut about 300 jobs from its Lincoln, Neb. payroll. The Swiss pharmaceutical company said Wednesday that the job cuts will occur over the next two years, leaving about 450 workers to concentrate on making three products: Excedrin, Theraflu and a veterinary medication, Sentinel.
Venaxis Appoints SomaLogic CMO and former Pfizer Executive Stephen A. Williams, M.D., Ph.D., to Board of DirectorsApril 19, 2013 11:17 am | News | Comments
Venaxis, Inc., an in vitro diagnostic company focused on obtaining FDA clearance and commercializing its CE Marked APPY1 Test, a rapid, protein biomarker-based assay for appendicitis, today announced the appointment of Stephen A. Williams, M.D., Ph.D., Chief Medical Officer at SomaLogic, to the Company's Board of Directors.
Advanced Clinical, a provider of clinical research solutions, today announced an addition to its leadership team: Julie A. Ross, has been hired as Executive Vice President, CRO Operations. Julie Ross is a tenured executive leader who has been instrumental in the development and the success of multiple clinical operations divisions.
Vanda Pharmaceuticals Inc., announced today that it has named Paolo Baroldi, M.D., Ph.D. as its Senior Vice President and Chief Medical Officer. Dr. Baroldi has over 30 years of clinical development experience in many therapeutic areas, including neurology and psychiatry. He has been working in the role of acting Chief Medical Officer with Vanda since October 1, 2012.
Catalent Pharma Solutions today announced that it has made two senior appointments to support its recently established joint ventures in China for its Softgel Technologies and Clinical Supply Solutions businesses. Dr. Weiyan “Jackson” Zhu has joined as Catalent's Country General Manager for China, while Yufeng (Paul) Cao becomes the new Site Operations Director, for the 31,000 sq ft Catalent Clinical Trial Supplies Co., Ltd facility
Oramed Pharmaceuticals Inc., a developer of oral drug delivery systems, today announced a key addition to its executive leadership team with the appointment of Joshua Hexter as Chief Operating Officer and Vice President of Business Development.
Matthew R. Stober has been named senior vice president, Operations, effective today. In addition to expanding his current U.S. responsibilities to assume leadership for all of Hospira's pharmaceutical manufacturing operations, Mr. Stober will have responsibility for the operations functions, including manufacturing science and technology, engineering, competitive strategy, health and safety, supply chain and procurement.
Aeterna Zentaris Inc. announced today that David A. Dodd has been appointed President and Chief Executive Officer of the Company, succeeding Juergen Engel, PhD. Mr. Dodd has also been appointed director on the Company's Board of Directors.
Celgene's Robert J. Hugin Becomes PhRMA Board Chairman; Ian C. Read, Kenneth C. Frazier Assume New PostsApril 12, 2013 1:40 pm | News | Comments
Robert J. Hugin, chairman and CEO of Celgene Corporation, was elected chairman of the Pharmaceutical Research and Manufacturers of America (PhRMA) today at the trade association's annual meeting. Also elected were Ian C. Read, president and CEO of Pfizer Inc, as chairman-elect of the PhRMA Board of Directors, and Kenneth C. Frazier, Chairman, President and CEO of Merck & Co, Inc., as Board treasurer.
Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Lynn Kramer, MD, to the newly created position of chief clinical officer of Eisai Product Creation Systems. In this role, Dr. Kramer will be responsible for the approval of protocol designs of pivotal studies to achieve timely regulatory approval of competitive labels for new products, indications and life-cycle extensions.
Shares of Delcath Systems Inc. slid further Tuesday after the medical device company said it will eliminate jobs and move its headquarters to reduce its spending. After the market closed on Monday, Delcath said it will cut costs by eliminating 21 percent of its staff positions. It also plans to move its New York City operations to a less expensive satellite office in New Jersey.
Bristol-Myers Squibb Co. will replace its top researcher with a physician and former medical school professor who has worked in pharmaceutical industry research for more than two decades. Dr. Francis Cuss, 58, will become the New York-based drugmaker's executive vice president and chief...
Bristol-Myers Squibb Announces Appointment of Francis Cuss as Executive Vice President and Chief Scientific OfficerApril 8, 2013 7:56 am | News | Comments
Bristol-Myers Squibb Company today announced the appointment of Francis Cuss, MB BChir, FRCP, 58, as executive vice president and chief scientific officer, effective July 1 after Elliott Sigal, M.D., Ph.D., 61, retires. Dr. Sigal has served as the company’s chief scientific officer since 2004 and on the company’s Board of Directors since 2011. He will retire from both positions effective June 30, 2013.
Teva Pharmaceutical Industries Ltd. today announced the appointment of Ichiro Kikushige as Chief Executive Officer (CEO) of Teva Seiyaku, Japan, effective on May 15, 2013. Mr. Kikushige most recently was Senior Director of Sales for Eli Lilly Japan K.K. Mr. Kikushige will replace Makoto Shimada, currently President and CEO of Teva Seiyaku.
Bristol-Myers Squibb Co. said Thursday it is closing Amylin Pharmaceuticals' headquarters in San Diego and eliminating about 300 positions at the facility. Bristol-Myers said in a statement all the work that is done in the San Diego facility will move to other locations by the end of 2014, and...
Barbara Piasecka Johnson, a Polish farmer's daughter who worked as a maid for an American heir to the Johnson & Johnson fortune before marrying him and eventually inheriting much of his wealth, has died at the age of 76. Johnson, the widow of J. Seward Johnson Sr., became embroiled in a nasty and prominent legal battle when her husband died in 1983.
Drugstore operator CVS Caremark Corp.'s board of directors has elected former Johnson & Johnson Chairman and CEO William C. Weldon to join the board. The Woonsocket, R.I., company late Friday said that Weldon's experience in managing a complex health care company and his knowledge of the...
Struggling drug company AstraZeneca PLC says it will cut some 2,300 jobs worldwide as part of a restructuring plan. The company said Thursday the cuts are in addition to a previously announced program cutting 1,600 positions related to research and development announced March 18 and the elimination of 1,150 positions announced last year.
British drugmaker AstraZeneca PLC is eliminating 1,600 jobs, mostly in the U.S. and United Kingdom, under a global restructuring meant to reduce costs and make research programs more productive. The cuts amount to nearly 3 percent of AstraZeneca's 57,200 workers around the world.